FOLH1 and prostate cancer: Finally, to confirm whether 212Pb-ADVC001 would demonstrate a strong antitumor efficacy in prostate cancer lesions expressing an intermediate level of PSMA, a single-dose efficacy study was performed in the PSMA-positive C4-2 xenograft model in NSG mice (Fig. 6) that express a lower level of PSMA than PC3-PIP cells (Supplemental Fig. 1).